Composition for relieving skin irritation, comprising lipid complex

Abstract

The present specification relates to a composition which comprises a ceramide or a pseudo-ceramide and a lipid complex including a fatty acid, and thus forms a stable formulation and relieves skin irritation. According to the present disclosure, the composition comprises a lipid complex having a structure similar to that of the stratum corneum, and thus can exhibit an excellent skin irritation relief effect when applied to sensitive skin.

Description

Composition for alleviating skin irritation containing a lipid complex

[0001] Cross-reference to related applications

[0002] This application claims priority to Republic of Korea Patent Application No. 10-2024-0098385, filed July 25, 2024, and Republic of Korea Patent Application No. 10-2025-0087958, filed July 1, 2025, the entire contents of which are incorporated herein by reference.

[0003] Disclosed herein is a composition comprising a lipid complex comprising ceramide or a similar ceramide and a fatty acid, which has a stable formulation and has a skin irritation alleviating effect.

[0004] Human skin is a part directly exposed to the external environment, and recently, environmental pollution has become serious, and the skin is easily damaged due to increased ultraviolet ray exposure due to ozone layer destruction, dry living spaces, individual allergies, stress, and increased exposure to chemical toxic substances. As a result, various irritants are generated, and the skin easily turns red or becomes sensitive.

[0005] Many cosmetics manufacturers are showing increasing interest in substances that soothe irritation in cosmetics, and various raw materials are being developed.

[0006] In one aspect of the present disclosure, it is intended to provide a composition that can alleviate skin sensitivity while maintaining a stable formulation by including a lipid complex as an active ingredient.

[0007] In one aspect, the present disclosure provides a composition for alleviating skin irritation, comprising a lipid complex as an active ingredient, wherein the lipid complex comprises: a nucleating agent; a pseudokeratin lipid lamellar layer comprising a ceramide or a ceramide analogue positioned on the nucleating agent; and a polymer layer on the pseudokeratin lipid lamellar layer.

[0008] In one aspect, the composition for relieving skin irritation according to the present disclosure includes a lipid complex having a structure similar to the stratum corneum of the skin, which has excellent phase stability and can contain a large amount of moisture and useful active substances, and thus can exhibit an excellent skin irritation relieving effect when applied to sensitive skin.

[0009] Figure 1 shows the skin irritation alleviation effect of a composition according to one embodiment of the present disclosure.

[0010] Hereinafter, the present disclosure will be described in more detail through the following examples. However, the following examples are provided solely for illustrative purposes to aid understanding of the present disclosure, and the scope and range of the present disclosure are not limited thereto.

[0011] In an exemplary embodiment of the present disclosure, a composition for alleviating skin irritation is provided, comprising a lipid complex as an active ingredient, wherein the lipid complex comprises: a nucleating agent; a pseudokeratin lipid lamellar layer comprising a ceramide or a ceramide analogue positioned on the nucleating agent; and a polymer layer on the pseudokeratin lipid lamellar layer.

[0012] In another exemplary embodiment of the present disclosure, a method of soothing skin irritation is provided, comprising applying a lipid complex to the skin, the lipid complex comprising: a nucleating agent; a pseudokeratin lipid lamella layer comprising a ceramide or a ceramide analog as an active ingredient; and a polymer layer on the pseudokeratin lipid lamella layer.

[0013] In another exemplary embodiment of the present disclosure, a use of a lipid complex for preparing a composition for soothing skin irritation is provided, the lipid complex comprising: a nucleating agent; a pseudokeratin lipid lamella layer comprising a ceramide or a ceramide analog as an active ingredient; and a polymer layer on the pseudokeratin lipid lamella layer.

[0014] In another exemplary embodiment of the present disclosure, a non-therapeutic use of a lipid complex for alleviating skin irritation is provided, the lipid complex comprising: a nucleating agent; a pseudokeratin lipid lamellae layer comprising a ceramide or a ceramide analog as an active ingredient; and a polymer layer on the pseudokeratin lipid lamellae layer.

[0015] The above-mentioned nucleating agent may be a colloid that is inactive and can be easily disintegrated by external stimuli.

[0016] In one embodiment, the nucleating agent may be selected from the group consisting of sugar, salt, hyaluronic acid, alginic acid, chondroitin sulfate, chitosan, chitin, polylysine, collagen, gelatin, stearic acid, cetyl alcohol, stearyl alcohol, and mixtures thereof.

[0017] In one embodiment, the nucleating agent may be included in an amount of 15 to 45 wt% based on the total weight of the lipid complex. When the amount of the nucleating agent is used within the above range, not only can aggregation that may occur during the process of coating a pseudokeratin lipid lamellar layer, polymer layer, etc. on the surface of the nucleating agent be reduced, but the coating rate can also be increased, thereby enhancing the structural stability of the lipid complex, which is the final product.

[0018] For example, the nucleating agent may be at least 15 wt%, at least 20 wt%, at least 25 wt%, at least 30 wt%, at least 35 wt%, or at least 40 wt%, and may be at most 45 wt%, at most 40 wt%, at most 30 wt%, at most 25 wt%, or at most 20 wt%, based on the total weight of the lipid complex.

[0019] As mentioned above, the stratum corneum is located on the nucleus. The stratum corneum of human skin is composed of keratinocytes and intercellular lipids, and functions as a unique barrier to the skin. The intercellular lipids of the keratinocytes play the most crucial role in this barrier function, and have a multilayered lamellar structure. The pseudokeratinocyte lipid lamellar layer is a layer that substantially mimics the structure of intercellular lipids of the keratinocytes with a lamellar structure.

[0020] The above-mentioned stratum corneum lipid lamellae layer contains ceramides, which function to protect the body from stress by removing damaged cells when cells are damaged due to internal or external stress. As the skin ages, the content of ceramides within the stratum corneum decreases, which can lead to loss of skin moisture, exposure to external stimuli such as ultraviolet rays or chemicals, and exfoliation of keratinocytes, which can make the skin surface sensitive. Therefore, by supplying ceramides or ceramide analogs to the skin from the outside, the degree of irritation of sensitive skin can be alleviated.

[0021] In one embodiment, the ceramide or ceramide analogue may include at least one selected from the group consisting of ceramide 1 (ceramide EOP), ceramide 2 (ceramide NS), ceramide 3 (ceramide NP), ceramide 4, ceramide 5 (ceramide AS), ceramide 6 (ceramide AP), Hydroxypropyl Bispalmitamide MEA, Dihydroxyisopropyl Palmoylpalmamide, and Cetyl-PG Hydroxyethyl Palmitamide.

[0022] For example, the ceramide or ceramide analogue may include one or more of Hydroxypropyl Bispalmitamide MEA and Cetyl-PG Hydroxyethyl Palmitamide.

[0023] In one embodiment, the pseudokeratin lipid lamellar layer may be included in an amount of 40 to 80 wt% based on the total weight of the lipid complex.

[0024] For example, the keratin-like lipid lamella layer may be at least 40 wt%, at least 50 wt%, at least 60 wt%, or at least 70 wt%, and may be at most 80 wt%, at most 70 wt%, at most 60 wt%, or at most 50 wt%, based on the total weight of the lipid complex.

[0025] In one embodiment, the concentration of the ceramide or ceramide analog may be 15 to 45 wt% based on the total weight of the lipid complex. When this range is satisfied, the formulation may exhibit a skin irritation-alleviating effect while being stable and free of skin toxicity.

[0026] For example, the concentration of the ceramide or ceramide analog may be at least 15 wt%, at least 20 wt%, at least 25 wt%, at least 30 wt%, at least 35 wt%, or at least 40 wt%, and may be at most 45 wt%, at most 40 wt%, at most 30 wt%, at most 25 wt%, or at most 20 wt%, based on the total weight of the lipid complex.

[0027] In one embodiment, the pseudokeratin lipid lamellae may further comprise a fatty acid; cholesterol or a derivative thereof; or a mixture thereof.

[0028] In one embodiment, the fatty acid may be an unsaturated or saturated fatty acid having 8 to 30 carbon atoms. For example, the fatty acid may include one or more selected from the group consisting of stearic acid, myristic acid, arachidonic acid, palmitic acid, oleic acid, and behenic acid.

[0029] In one embodiment, the cholesterol or a derivative thereof may include at least one selected from the group consisting of cholesterol, cholesteryl chloride, cholesteryl octanoate, cholesteryl nonanoate, cholesteryl oleyl carbonate, cholesteryl isostearyl carbonate, and mixtures thereof.

[0030] In one embodiment, the pseudokeratin lipid lamellae may comprise ceramide or a ceramide analog, a fatty acid, and cholesterol or a derivative thereof.

[0031] In one embodiment, the ceramide or ceramide analog; fatty acid; and cholesterol or a derivative thereof; may be included in a weight ratio of 1:0.1 to 10:0.01 to 1.

[0032] For example, the weight ratio of the ceramide or ceramide analog; fatty acid; and cholesterol or a derivative thereof may be 1:0.1 to 10:0.01 to 1, 1:0.2 to 5:0.01 to 0.9, 1:0.5 to 3:0.01 to 0.5, or 1:0.8 to 2:0.01 to 0.1.

[0033] A polymer layer is located on the pseudokeratin lipid lamellar layer. The polymer layer surrounds the outside of the pseudokeratin lipid lamellar layer and protects the pseudokeratin lipid lamellar layer, thereby significantly improving the structural stability of the lipid complex.

[0034] The polymer layer is not particularly limited as long as it does not easily dissolve in a solvent, such as water or a polar organic solvent, and can be evenly coated on the surface of the pseudokeratin lipid lamellar layer, and may be a natural polymer or a synthetic polymer.

[0035] Natural polymers that make up the polymer layer include, for example, hyaluronic acid, corn starch alginic acid, pectin, carrageenan, chondroitin sulfate, dextran sulfate, chitosan, chitin, polylysine, collagen, and fibrin.

[0036] In addition, synthetic polymers constituting the polymer layer include, for example, polyethylene glycol-polylactic acid-polyethylene glycol (PEGPLA-PEG), polyethylene glycol-poly(lactic co-glycolic acid)-polyethylene glycol (PEG-PLGA-PEG), polyethylene glycol-polycaprolactone-polyethylene glycol (PEG-PCL-PEG), polyethylene-bis-(polylactic acid-acrylate), and phosphorus(isopropylacrylamide-co-acrylic acid).

[0037] In addition, polymers usable in the present disclosure include polystyrene, poly p- or m-methylstyrene, poly p- or m-ethylstyrene, poly p- or m-chlorostyrene, poly p- or m-chloromethylstyrene, polystyrenesulfonic acid, poly p- or m- or t-butoxystyrene, polymethyl(meth)acrylate, polyethyl(meth)acrylate, polypropyl(meth)acrylate, polyn-butyl(meth)acrylate, polyisobutyl(meth)acrylate, polyt-butyl(meth)acrylate, poly 2-ethylhexyl(meth)acrylate, poly n-octyl(meth)acrylate, polylauryl(meth)acrylate, polystearyl(meth)acrylate, poly 2-hydroxyethyl(meth)acrylate, polyethyleneglycol(meth)acrylate, Unsaturated carboxylic acids such as methoxypolyethylene glycol (meth)acrylate, polyglycidyl (meth)acrylate, polydimethylaminoethyl (meth)acrylate, polydiethylaminoethyl (meth)acrylate, polyvinylacetate, polyvinylpropionate, polyvinyl butyrate, polyvinyl ether, polyallyl butyl ether, polyallyl glycidyl ether, poly(meth)acrylic acid, polymaleic acid, polyalkyl(meth)acrylamide, poly(meth)acrylonitrile, etc. can be used in combination.

[0038] For example, the polymer layer may include an acrylates / ammonium methacrylate copolymer.

[0039] In one embodiment, the polymer layer may be included in an amount of 0.01 to 5 wt% based on the total weight of the lipid complex. When the amount of the polymer layer is used within the above range, the stability of the lipid complex can be increased, and the final product, the lipid complex, can be applied to external skin preparations such as cosmetics without causing a foreign body sensation.

[0040] For example, the content of the polymer layer may be 0.01 wt% or more, 0.1 wt% or more, 1 wt% or more, 2 wt% or more, 3 wt% or more, or 5 wt% or less, 4 wt% or less, 3 wt% or less, 2 wt% or less, 1 wt% or less, or 0.1 wt% or less, based on the total weight of the lipid complex.

[0041] The lipid complex according to the present disclosure can be manufactured through various coating methods, and for example, can be manufactured according to the method disclosed in Korean Patent No. 10-1499733.

[0042] In one embodiment, the lipid complex may be included in an amount of 0.01 to 30 wt% based on the total weight of the composition. When the above range is met, there are advantages in superior formulation stability, usability, and skin irritation relief.

[0043] For example, the content of the lipid complex may be 0.01 wt% or more, 0.05 wt% or more, 0.1 wt% or more, 0.5 wt% or more, 1 wt% or more, 1.5 wt% or more, 2 wt% or more, 2.5 wt% or more, 3 wt% or more, 5 wt% or more, 10 wt% or more, 15 wt% or more, 20 wt% or more, or 25 wt% or more, and may be 30 wt% or less, 25 wt% or less, 20 wt% or less, 15 wt% or less, 10 wt% or less, or 5 wt% or less, 3 wt% or less, 2.5 wt% or less, 2 wt% or less, 1.5 wt% or less, 1 wt% or less, 0.5 wt% or less, 0.1 wt% or less, or 0.05 wt% or less, based on the total weight of the composition.

[0044] In one embodiment, the composition may be a topical skin preparation.

[0045] The above skin external application agent is a general term that can include anything applied externally to the skin, and various types of cosmetics can be included here.

[0046] In one embodiment, the composition may be a cosmetic composition.

[0047] In one embodiment, the external form of the cosmetic composition may contain a cosmetically or dermatologically acceptable medium or base. This may be provided in any formulation suitable for topical application, for example, in the form of a solution, gel, solid, anhydrous paste, an emulsion obtained by dispersing an oil phase in an aqueous phase, a suspension, a microemulsion, a microcapsule, a microgranule, or a vesicular dispersion of ionic (liposomes) and non-ionic forms, or in the form of a cream, toner, lotion, powder, ointment, spray, or concealer stick. These compositions may be prepared according to methods conventional in the art. The composition according to the present disclosure may also be used in the form of a foam or in the form of an aerosol composition further containing a compressed propellant.

[0048] The cosmetic composition according to the present disclosure is not particularly limited in its formulation, and may be formulated as cosmetics such as, for example, a softening toner, an astringent toner, a nourishing toner, a nourishing cream, a massage cream, an essence, an eye cream, an eye essence, a cleansing cream, a cleansing foam, a cleansing water, a cleansing tissue containing the cosmetic composition, a pack, a powder, a body lotion, a body cream, a body oil, and a body essence.

[0049] When the formulation of the cosmetic composition according to the present disclosure is a paste, cream or gel, animal fiber, plant fiber, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as a carrier component.

[0050] When the formulation of the cosmetic composition according to the present disclosure is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and particularly in the case of a spray, a propellant such as chlorofluorohydrocarbon, propane / butane or dimethyl ether may be additionally included.

[0051] In the case where the formulation of the cosmetic composition according to the present disclosure is a solution or emulsion, a solvent, solvating agent or emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid ester of sorbitan.

[0052] When the formulation of the cosmetic composition according to the present disclosure is a suspension, a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tragacanth, etc. can be used as a carrier component.

[0053] The cosmetic composition according to the present disclosure may further include functional additives and ingredients included in general cosmetic compositions. The functional additives may include ingredients selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, high molecular weight peptides, high molecular weight polysaccharides, squalane, sphingolipids, and seaweed extract.

[0054] The cosmetic composition according to the present disclosure may also contain, as necessary, ingredients included in general cosmetic compositions in addition to the functional additives described above. Examples of other ingredients to be contained include fat components, moisturizers, emollients, emulsifiers, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, sterilizers, antioxidants, plant extracts, pH adjusters, alcohols, pigments, fragrances, blood circulation promoters, cooling agents, antiperspirants, purified water, and the like.

[0055] In one embodiment, the composition may be a food composition.

[0056] In one embodiment, the composition may be a non-therapeutic oral composition.

[0057] The food composition or non-therapeutic oral composition according to the present disclosure may be in the form of a liquid or solid formulation, and may be in the form of a tablet, capsule, soft capsule, pill, granule, beverage (drink), diet bar, chocolate, caramel formulation, or confectionery formulation, and the formulation is not particularly limited.

[0058] The food composition or non-therapeutic oral composition according to the present disclosure may further contain excipients, sugars, flavors, pigments, oils, proteins, etc., as needed, in addition to the above-described active ingredients.

[0059] In one embodiment, the composition may be a pharmaceutical composition.

[0060] In one embodiment, the composition is a pharmaceutical composition for preventing, treating or improving one or more selected from the group consisting of erythema, atopy, itching, psoriasis and dry skin.

[0061] A pharmaceutical composition according to one embodiment of the present disclosure may additionally contain pharmaceutical adjuvants such as preservatives, stabilizers, wetting agents or emulsifying agents, salts for osmotic pressure control, and / or buffers, and other therapeutically useful substances, and may be formulated into various oral or parenteral dosage forms according to conventional methods.

[0062] The oral dosage forms include, for example, tablets, pills, hard and soft capsules, solutions, suspensions, emulsions, syrups, powders, granules, granules, pellets, etc., and these dosage forms may contain, in addition to the active ingredient, a surfactant, a diluent (e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, and glycine), and a lubricant (e.g., silica, talc, stearic acid and its magnesium or calcium salts, and polyethylene glycol). The tablets may also contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, and polyvinylpyrrolidine, and optionally pharmaceutical additives such as disintegrating agents such as starch, agar, alginic acid or its sodium salt, absorbents, coloring agents, flavoring agents, and sweetening agents. The tablets may be manufactured by conventional mixing, granulating, or coating methods.

[0063] In addition, the above parenteral administration form may be a transdermal administration formulation, and examples thereof include, but are not limited to, injections, drops, ointments, lotions, gels, creams, sprays, suspensions, emulsions, suppositories, patches, etc.

[0064] Hereinafter, the present disclosure will be described in more detail through the following examples. However, the following examples are provided solely for illustrative purposes to aid understanding of the present disclosure, and the scope and range of the present disclosure are not limited thereto.

[0065] Example

[0066] 1. Preparation of a ceramide-containing lipid complex and a composition containing the same

[0067] The lipid complexes included in Examples 2-4 below were prepared using the same method as described in the examples of Korean Patent No. 10-1499733, and then the final composition was prepared by changing only the water content compared to the vehicle of Example 1.

[0068] [Full composition of each lipid complex]

[0069] Hydroxypropyl Bispalmitamide MEA Lipid Complex (Example 2) CERAMIDE NP Lipid Complex (Example 3) Cetyl-PG Hydroxyethyl Palmitamide Lipid Complex (Example 4) HYDROXYPROPYL BISPALMITAMIDE MEA (Ceramide Analogue) 32.8 CERAMIDE NP (Ceramide Analogue) 32.8 CETYL-PG HYDROXYETHYL PALMITAMIDE (Ceramide Analogue) 32.8 STEARIC ACID (Fatty Acid) 30.5 30.5 30.5 MANNITOL (Nucleating Agent) 28.3 28.3 28.3 HYDROGENATED LECITHIN (Lamellar Layer) 4.4 4.4 4.4 ACRYLATES / AMMONIUM METHACRYLATE COPOLYMER (Polymer Layer) 2.2 2.2 2.2 CHOLESTEROL (Cholesterol) 0.80.80.8SILICA (lamellar layer) 0.50.50.5ARACHIDIC ACID (fatty acid) 0.30.30.3PALMITIC ACID (fatty acid) 0.10.10.1OLEIC ACID (fatty acid) 0.10.10.1

[0070] No. Test Sample 1 Vehicle (DI Water 60%, 1,3-BG 39.6%, CARBOMER 0.4%) 2 Hydroxypropyl Bispalmitamide MEA Lipid Complex 20%+ Vehicle (DI Water 40%, 1,3-BG 39.6%, CARBOMER 0.4%) 3 CERAMIDE NP Lipid Complex 20%+ Vehicle (DI Water 40%, 1,3-BG 39.6%, CARBOMER 0.4%) 4 Cetyl-PG Hydroxyethyl Palmitamide Lipid Complex 20%+ Vehicle (DI Water 40%, 1,3-BG 39.6%, CARBOMER 0.4%)

[0071] Exam example

[0072] 1. Test method for skin irritation relief effect of ceramide-containing lipid complex

[0073] To confirm the skin irritation relief effect of a lipid complex containing ceramide, a single skin irritation test was conducted on 25 healthy adults (2 males, 23 females, average age: 42.1 years) (February 20, 2024 - February 23, 2024, Safety Lab, Amorepacific Technology Research Center).

[0074] On the first day of the study, a patch was attached to the upper back of the subject, and after 48 hours, the patch was removed. The first reading was performed 30 minutes later, and the second reading was performed 24 hours later. In order to determine the intensity of skin irritation of the sample, the average skin reactivity was calculated by assigning weights according to the degree of positive skin reaction and determining the skin irritation of the sample. The test was performed based on the terminology presented in [Table 1], which is a modified test standard from the ICDRG, CTFA guideline (1981) and the test standard of Frosch & Kligman (1979). The test results were calculated as the average value of the reaction for each subject.

[0075] ①Test materials

[0076] - Van der Bend Patch test chambers (Van der Bend Medical Supplies, Netherlands), Marking pen; Oil ink pen

[0077] ② Criteria for judging skin reactions

[0078] - modified from Frosch & Kligman and CTFA safety testing guidelines (Table 1)

[0079] -No visible reaction1+Slight erythema, either spotty or diffuse2+Moderate uniform erythema3+Intense erythema with edema4+Intense erythema with edema & vesicles

[0080] 2. Skin irritation relief effect of lipid complex containing ceramide

[0081] Referring to Tables 3 and 4 below, the vehicle prescription containing 60% DI Water, 39.6% BG, and 0.4% CARBOMER showed a 1-point reaction in 5 subjects in the first test and a 1-point reaction in 4 subjects in the second test, showing an average stimulation score of 0.36.

[0082] In the second prescription containing 6.55% Hydroxypropyl Bispalmitamide MEA (the content of Hydroxypropyl Bispalmitamide MEA in the lipid complex is 32.8%, and the content of Hydroxypropyl Bispalmitamide MEA in the entire composition is 6.55% by calculating the ratio of 32.8% of the 20% content of lipid complex in the composition, and the same content hereinafter), 2 people scored 1 point in the first test and 2 people scored 1 point in the second test, and the average stimulation was evaluated as 0.16. In addition, in the 3rd prescription containing CERAMIDE NP 6.55%, 0 people scored 1 point in the first test, 2 people scored 1 point in the second test, and the average stimulation was evaluated as 0.08. In the 4th prescription containing Cetyl-PG Hydroxyethyl Palmitamide 6.55%, 2 people scored 1 point in the first test, and 3 people scored 1 point in the second test, and the average stimulation was evaluated as 0.16.

[0083] Therefore, all prescriptions 2-4 showed a decrease in irritation level compared to the vehicle, and when the lipid complex containing Hydroxypropyl Bispalmitamide MEA, Ceramide NP, and Cetyl-PG Hydroxyethyl Palmitamide was included, irritation was reduced by 55.56%, 77.78%, and 55.56%, respectively. (See Figure 1)

[0084] [48-hour patch test]

[0085] NO Test Sample 1st Test 2nd Test Stimulus Average 123412341Vehicle (DI Water 60%, 1,3-BG 39.6%, CARBOMER 0.4%) 500040000.362Hydroxypropyl Bispalmitamide MEA Lipid Complex 20%+ Vehicle (DI Water 40%, 1,3-BG 39.6%, CARBOMER 0.4%) (PC-104 Dermaon in Figure 1) 200020000.163CERAMIDE NP Lipid Complex 20%+ Vehicle (DI Water 40%, 1,3-BG 39.6%, CARBOMER 0.4%) (NP Dermaon in Figure 1) 000020000.084Cetyl-PG Hydroxyethyl Palmitamide Lipid Complex 20%+ Vehicle (DI Water 40%, 1,3-BG 39.6%, CARBOMER 0.4%) (Cermoist Dermaon in Fig. 1) 200030000.16

[0086] [Subject Information and Subject-Specific Data]

[0087] 1 2 3 4 Number Gender Age 1st Test 1st Test 1st Test 2nd Test 1st Test 2nd Test 1F360000000002M32000000003M43000000004F33000001005F42100000106F39000000007F51100000008F47000000009F441100001110F430111000111F48000101011 2F270100000013F430000000014F441110000015F440000000016F410000000017F350000000018F4500000000 19F570000000020F530000000021F470000000022F410000000023F500000000024M331000000025F3500000000

[0088] Specific examples

[0089] Specific example 1: A composition for alleviating skin irritation, comprising a lipid complex as an effective ingredient,

[0090] The above lipid complex is,

[0091] nuclear agent;

[0092] A pseudokeratin lipid lamellar layer comprising ceramide or ceramide analogues located on the above-mentioned nucleus; and

[0093] A composition for alleviating skin irritation, comprising a polymer layer on the pseudokeratin lipid lamellar layer.

[0094] Specific example 2: A composition for alleviating skin irritation, wherein the nucleating agent in Specific example 1 is selected from the group consisting of sugar, salt, hyaluronic acid, alginic acid, chondroitin sulfate, chitosan, chitin, polylysine, collagen, gelatin, stearic acid, cetyl alcohol, stearyl alcohol, and mixtures thereof.

[0095] Specific example 3: A composition for alleviating skin irritation, wherein the nucleating agent is included in an amount of 15 to 45 wt% based on the total weight of the lipid complex according to Specific example 1 or 2.

[0096] Specific Example 4: A composition for alleviating skin irritation, wherein the ceramide or ceramide analogue comprises at least one selected from the group consisting of ceramide 1 (ceramide EOP), ceramide 2 (ceramide NS), ceramide 3 (ceramide NP), ceramide 4, ceramide 5 (ceramide AS), ceramide 6 (ceramide AP), hydroxypropyl bispalmitamide MEA, dihydroxyisopropyl palmoylpalmamide, and cetyl-PG hydroxyethyl palmitamide.

[0097] Specific example 5: A composition for alleviating skin irritation, wherein the pseudokeratin lipid lamellar layer is included in an amount of 40 to 80 wt% based on the total weight of the lipid complex in any one of Specific examples 1 to 4.

[0098] Specific example 6: A composition for alleviating skin irritation, wherein the concentration of the ceramide or ceramide analogue in any one of Specific examples 1 to 5 is 15 to 45 wt% based on the total weight of the lipid complex.

[0099] Specific example 7: In any one of Specific examples 1 to 6, the pseudokeratin lipid lamella layer is

[0100] fatty acid;

[0101] Cholesterol or its derivatives;

[0102] A composition for relieving skin irritation, further comprising a mixture thereof.

[0103] Specific example 8: A composition for alleviating skin irritation, wherein the fatty acid is an unsaturated or saturated fatty acid having 8 to 30 carbon atoms, in any one of Specific examples 1 to 7.

[0104] Specific example 9: A composition for alleviating skin irritation, wherein in any one of Specific examples 1 to 8, the cholesterol or a derivative thereof comprises at least one selected from the group consisting of cholesterol, cholesteryl chloride, cholesteryl octanoate, cholesteryl nonanoate, cholesteryl oleyl carbonate, cholesteryl isostearyl carbonate, and mixtures thereof.

[0105] Specific example 10: A composition for alleviating skin irritation, wherein the ceramide or ceramide analog, fatty acid, and cholesterol or derivative thereof are included in a weight ratio of 1:0.1 to 10:0.01 to 1 in any one of Specific examples 1 to 9.

[0106] Specific example 11: A composition for alleviating skin irritation, wherein the polymer layer is included in an amount of 0.01 to 5 wt% based on the total weight of the lipid complex in any one of Specific examples 1 to 3.

[0107] Specific example 12: A composition for alleviating skin irritation, wherein the lipid complex is included in an amount of 0.01 to 30 wt% based on the total weight of the composition in any one of Specific examples 1 to 11.

[0108] Specific example 13: A composition for alleviating skin irritation, wherein the composition is an external skin preparation according to any one of Specific examples 1 to 12.

[0109] Specific example 14: A composition for alleviating skin irritation, wherein the composition is a cosmetic composition according to any one of Specific examples 1 to 13.

[0110] Specific example 15: A composition for alleviating skin irritation, wherein the composition is a food composition according to any one of Specific examples 1 to 14.

[0111] Specific example 16: A composition for alleviating skin irritation, wherein the composition is a pharmaceutical composition according to any one of Specific examples 1 to 15.

Claims

1. A composition for relieving skin irritation, comprising a lipid complex as an active ingredient, The above lipid complex is, nuclear agent; A pseudokeratin lipid lamellar layer comprising ceramide or ceramide analogues located on the above-mentioned nucleus; and A composition for alleviating skin irritation, comprising a polymer layer on the pseudokeratin lipid lamellar layer.

2. In paragraph 1, A composition for alleviating skin irritation, wherein the nucleating agent is selected from the group consisting of sugar, salt, hyaluronic acid, alginic acid, chondroitin sulfate, chitosan, chitin, polylysine, collagen, gelatin, stearic acid, cetyl alcohol, stearyl alcohol and mixtures thereof.

3. In paragraph 1, A composition for alleviating skin irritation, wherein the nucleating agent is included in an amount of 15 to 45 wt% based on the total weight of the lipid complex.

4. In paragraph 1, A composition for alleviating skin irritation, wherein the ceramide or ceramide analogue comprises at least one selected from the group consisting of ceramide 1 (ceramide EOP), ceramide 2 (ceramide NS), ceramide 3 (ceramide NP), ceramide 4, ceramide 5 (ceramide AS), ceramide 6 (ceramide AP), hydroxypropyl bispalmitamide MEA, dihydroxyisopropyl palmoylpalmamide, and cetyl-PG hydroxyethyl palmitamide.

5. In paragraph 1, A composition for alleviating skin irritation, wherein the pseudokeratin lipid lamellar layer is included in an amount of 40 to 80 wt% based on the total weight of the lipid complex.

6. In paragraph 1, A composition for alleviating skin irritation, wherein the concentration of the ceramide or ceramide analogue is 15 to 45 wt% based on the total weight of the lipid complex.

7. In paragraph 1, The above pseudokeratin lipid lamellar layer is fatty acid; Cholesterol or its derivatives; A composition for relieving skin irritation, further comprising a mixture thereof.

8. In paragraph 7, A composition for alleviating skin irritation, wherein the fatty acid is an unsaturated or saturated fatty acid having 8 to 30 carbon atoms.

9. In paragraph 7, A composition for alleviating skin irritation, wherein the cholesterol or a derivative thereof comprises at least one selected from the group consisting of cholesterol, cholesteryl chloride, cholesteryl octanoate, cholesteryl nonanoate, cholesteryl oleyl carbonate, cholesteryl isostearyl carbonate, and mixtures thereof.

10. In paragraph 7, A composition for alleviating skin irritation, comprising the ceramide or ceramide analogue, fatty acid and cholesterol or derivative thereof in a weight ratio of 1:0.1 to 10:0.01 to 1.

11. In paragraph 7, A composition for alleviating skin irritation, wherein the polymer layer is included in an amount of 0.01 to 5 wt% based on the total weight of the lipid complex.

12. In paragraph 1, A composition for alleviating skin irritation, wherein the lipid complex is included in an amount of 0.01 to 30 wt% based on the total weight of the composition.

13. In paragraph 1, The above composition is a composition for external use on the skin, for relieving skin irritation.

14. In paragraph 1, The above composition is a cosmetic composition, a composition for alleviating skin irritation.

15. In paragraph 1, The above composition is a food composition, a composition for alleviating skin irritation.

16. In paragraph 1, The above composition is a pharmaceutical composition, a composition for relieving skin irritation.

Images